Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of
- PDF / 1,862,600 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 47 Downloads / 154 Views
ORIGINAL RESEARCH
Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Metaanalysis of Randomized Studies Dan Liu . Hao Chen . Fang Song . Mohamad Anis Ahmed . Hongyan Wu Received: July 29, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Type 2 diabetes mellitus (T2DM) is becoming a major issue worldwide. To effectively control the blood sugar of patients with T2DM, several novel oral hypoglycemic agents (OHAs) are being developed. Sodium/glucose co-transporter 2 (SGLT 2) inhibitors have recently shown beneficial outcomes in patients with T2DM. In this analysis, we aimed to systematically compare the adverse drug events observed with ipragliflozin versus placebo for the treatment of patients with T2DM. Methods: http://www.ClinicalTrials.gov, the bibliographic database of life science and Drs. Dan Liu and Hao Chen contributed equally to this article and are the first co-authors.
Digital Features This article is published with digital features to facilitate understanding of the article. You can access the digital features on the article’s associated Figshare page. To view digital features for this article, go to https://doi.org/10.6084/m9.figshare.12789212. D. Liu H. Chen F. Song H. Wu (&) Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou First People’s Hospital, Jingzhou, Hubei, People’s Republic of China e-mail: [email protected] M. A. Ahmed Department of Cardiology, Peking University People’s Hospital, Beijing, People’s Republic of China
biomedical information MEDLINE, EMBASE and the Cochrane Central were searched for English publications satisfying the inclusion and exclusion criteria of this study. Adverse drug events were the end points in this analysis. The latest version (5.4) of the RevMan software was used to analyze the data, and risk ratios (RR) with 95% confidence intervals (CI) were used to represent the data post analysis. Results: Eight randomized studies with a total of 1519 participants with T2DM were included in this analysis whereby total treatment-emergent adverse events (RR: 1.06, 95% CI: 0.96–1.16; P = 0.26), including mild (RR: 0.95, 95% CI: 0.79–1.13; P = 0.54), moderate (RR: 1.04, 95% CI: 0.72–1.51; P = 0.83) and severe treatment-emergent adverse events (RR: 0.72, 95% CI: 0.26–1.96; P = 0.52), were not significantly different in those patients who were assigned to ipragliflozin versus placebo for the treatment of T2DM. Moreover, drug-related adverse events (RR: 1.04, 95% CI: 0.69–1.58; P = 0.85), adverse events leading to drug discontinuation (RR: 1.09, 95% CI: 0.57–2.10; P = 0.79), urinary tract infection (RR: 1.03, 95% CI: 0.60–1.77; P = 0.91), naso-pharyngitis (RR: 0.54, 95% CI: 0.19–1.52; P = 0.25), constipation (RR: 1.94, 95% CI: 0.90–4.20; P = 0.09), dizziness (RR: 0.81, 95% CI: 0.20–3.23; P = 0.76), gastrointestinal disorders (RR: 0.96, 95% CI: 0.68–1.36; P = 0.82) and dehydration (RR: 2.26, 95% CI: 0.
Data Loading...
